New drug combo targets ALS inflammation in genetically selected patients
Disease control
Not yet recruiting
This study tests whether combining two drugs (galunisertib and nerandomilast) can slow the progression of ALS in 60 people who have high levels of a protein called GREM2. The drugs aim to reduce brain inflammation and nerve cell damage. Participants will receive either the drug c…
Phase: PHASE2, PHASE3 • Sponsor: Gipfel Life Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC